1Pestova E,Millichap JJ,Noskin GA, Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones [J]. Antimicrob chemother,2000, 45 (5): 583.
2Fukuda H,Hiramatsu K. Primary targets of fluoroquinolones in streptococcus pnenmonlae [J]. Antimierob Agents chemother,1999,43(2):410.
3Takei M, Fukuda H, Yasue T,et al. Inhibitory activities of gatifloxacin (AM-1155) ,a newly developed fluoroquinolone,against bacterial and mammalian type Ⅱ topoisomerase[J]. Antimicrob Agents Chemother, 1998,42 (10), 2678.
5Nakashima M, Uematsu T, Kosuge K, et al. single-and multipledose pharmaeokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans[J]. Antimicrob Agents chemother, 1995,39(12):2635.
6Takahashi S,Hirose T,Sano M,et al. Changes in susceptibility of pseudomonas aernginosa to gatifloxacin and carbapenem in an in vitro urinary bladder model[J]. Chemotherapy, 2000,46(3) :204.
7Fukuda H, Hori S, Hiramatsu K. Antibaeterialaetivity of gatifloxaein (AM-1155, CGSS01, BMS-206584 ), a newly developed fluoroquinolone: against sequentiallyacquired quinolone-resisrants mutants and the norA transformant of Straphylococcus aureus[J ]. Antimierob Agents Chemother, 1998,42 (8) : 1917.
